Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.
The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response *1
A Somavert patient demonstrates how the pre-filled diluent syringe enables straightforward reconstitution and administration at home
Find information on funding, initiation, homecare and follow-up
Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and BlueTeq funding arrangements to homecare service provision
To find out more about ACRODAT, supporting your patients or to order starter kits
Help your patients feel confident with Somavert and self-administration
1. Somavert Summary of Product Characteristics. Available here
2. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-7
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020